上海莱士(002252) - 2023 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2023 reached ¥2,034,744,817.97, representing a 22.72% increase compared to the same period last year[3]. - Net profit attributable to shareholders for Q3 2023 was ¥548,605,548.04, a slight increase of 1.08% year-on-year[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥603,604,791.17, up 11.36% from the previous year[3]. - Total operating revenue for the current period reached ¥5,935,370,613.02, a 19.9% increase from ¥4,951,543,979.15 in the previous period[25]. - Net profit for the current period was ¥1,785,618,617.73, representing a 11.6% increase compared to ¥1,599,553,187.66 in the previous period[26]. - Total comprehensive income for the current period was ¥2,242,597,415.86, down from ¥3,068,200,086.26 in the previous period[26]. Assets and Liabilities - The total assets at the end of Q3 2023 amounted to ¥31,912,459,945.21, reflecting a 4.78% increase from the end of the previous year[3]. - As of September 30, 2023, total assets amounted to approximately 31.91 billion yuan, an increase from 30.46 billion yuan at the beginning of the year[22]. - The total liabilities as of September 30, 2023, were approximately 2.09 billion yuan, compared to 1.64 billion yuan at the beginning of the year[23]. - The company's total equity increased to approximately 29.82 billion yuan as of September 30, 2023, from 28.81 billion yuan at the beginning of the year[23]. Cash Flow - The company's cash flow from operating activities for the year-to-date reached ¥1,940,451,824.32, a significant increase of 61.25% compared to the same period last year[7]. - Operating cash flow net amount was ¥1,940,451,824.32, an increase of 61.4% from ¥1,203,356,366.64 in the previous period[29]. - Cash and cash equivalents at the end of the period totaled ¥3,580,923,338.88, up from ¥2,243,907,832.11 at the end of the previous period[29]. - The company's cash and cash equivalents stood at approximately 4.02 billion yuan as of September 30, 2023, up from 3.98 billion yuan at the beginning of the year[21]. Shareholder Information - As of September 28, 2023, the total number of common shareholders is 103,398[9]. - GRIFOLS, S.A. holds 26.20% of shares, totaling 1,766,165,808 shares, making it the largest shareholder[9]. - The top ten shareholders include several state-owned and foreign entities, with significant stakes held by China Cinda Asset Management Co., Ltd. (4.14%) and China Huarong Asset Management Co., Ltd. (3.65%)[9]. - The company confirmed that there are no related party transactions among the top ten shareholders, except for certain relationships within the CITIC Group[10]. Share Repurchase Plan - The company has implemented a share buyback plan, resulting in a net cash outflow of ¥1,088,886,701.78 from financing activities[7]. - The company has repurchased a total of 136,153,070 shares, representing 2.0198% of the total share capital, with a total expenditure of approximately RMB 999.69 million[15]. - The highest repurchase price was RMB 7.56 per share, while the lowest was RMB 7.06 per share[15]. - The repurchase plan was approved with a total budget of between RMB 500 million and RMB 1 billion, with a maximum price of RMB 8.00 per share[12]. - The first repurchase occurred on July 14, 2023, with 6,531,878 shares bought back at a total cost of approximately RMB 48.78 million[13]. - The company has disclosed the progress of the share repurchase on multiple occasions, including on August 3, 5, and 21, 2023[14]. - The repurchase plan is set to be completed within 12 months from the approval date, contingent on specific conditions being met[12]. Employee Stock Ownership Plan (ESOP) - The employee stock ownership plan (ESOP) aims to use up to 33.77 million repurchased shares, accounting for approximately 0.50% of the total share capital of 674.08 million shares[16]. - The total amount of funds raised through the ESOP is expected to be no more than 121.91 million yuan, with actual subscription funds amounting to 113.17 million yuan as of September 25, 2023[16]. - The company has completed the non-trading transfer of 31.35 million shares to the ESOP account at a transfer price of 3.61 yuan per share, representing 0.47% of the total share capital[17]. Operational Metrics - The gross profit margin decreased due to an increase in the sales proportion of imported albumin, which has a lower gross margin compared to self-produced products[7]. - The company reported a 19.87% increase in total revenue for the year-to-date, driven primarily by growth in imported albumin and immunoglobulin sales[6]. - The company experienced a 38.42% increase in accounts payable, mainly due to increased payables from agency import business[6]. - The company reported a decrease in contract liabilities by 88.63%, indicating a reduction in advance payments received[6]. - The company reported a decrease in accounts receivable from approximately 707.02 million yuan to 654.86 million yuan during the same period[21]. - The company’s inventory increased from approximately 3.27 billion yuan to 3.37 billion yuan as of September 30, 2023[21]. - Research and development expenses for the current period were ¥132,454,755.35, a 29.7% increase from ¥102,089,434.95 in the previous period[25].